Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 3
2004 9
2005 19
2006 21
2007 29
2008 41
2009 35
2010 67
2011 126
2012 154
2013 152
2014 207
2015 211
2016 221
2017 226
2018 229
2019 179
2020 20
Text availability
Article attribute
Article type
Publication date

Search Results

1,711 results
Results by year
Filters applied: . Clear all
Page 1
Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK, Amengual JE. Lue JK, et al. Curr Hematol Malig Rep. 2018 Oct;13(5):369-382. doi: 10.1007/s11899-018-0466-6. Curr Hematol Malig Rep. 2018. PMID: 30112706 Review.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Italiano A, et al. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650362 Clinical Trial.
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, Wei R, Zheng XL, Liu Z, Zhang X, Yang H, Hao B, Shen YY, Su Y, Cong X, Huang M, Tan M, Ding J, Geng M. Huang X, et al. Cell. 2018 Sep 20;175(1):186-199.e19. doi: 10.1016/j.cell.2018.08.058. Epub 2018 Sep 13. Cell. 2018. PMID: 30220457 Free article.
EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.
Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, Santoro R, Levesque MP, Sommer L. Zingg D, et al. Cancer Cell. 2018 Jul 9;34(1):69-84.e14. doi: 10.1016/j.ccell.2018.06.001. Epub 2018 Jun 28. Cancer Cell. 2018. PMID: 30008323 Free article.
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.
Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. Zhao Y, et al. EMBO J. 2019 Mar 1;38(5):e99599. doi: 10.15252/embj.201899599. Epub 2019 Feb 5. EMBO J. 2019. PMID: 30723117 Free PMC article.
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K. Chen L, et al. J Clin Invest. 2018 Jan 2;128(1):446-462. doi: 10.1172/JCI90793. Epub 2017 Dec 4. J Clin Invest. 2018. PMID: 29202477 Free PMC article.
1,711 results
Jump to page
Feedback